Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 04, 2018 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s...
Karyopharm Reports Updated Selinexor Data from the Phase 2b STORM and Phase 1b/2 STOMP Studies in Relapsed/Refractory Multiple Myeloma at the American Society of Hematology 2018 Annual Meeting
December 03, 2018 11:00 ET
|
Karyopharm Therapeutics Inc.
-- Oral Selinexor Achieves 26.2% Overall Response Rate in STORM Study, 4.4 Month Median Duration of Response, 8.6 Month Median Overall Survival and 15.6 Month Median Survival in Patients with MR or...
Karyopharm Reports Positive Top-Line Phase 2b SADAL Data for Selinexor in Patients with Diffuse Large B-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting
December 01, 2018 12:00 ET
|
Karyopharm Therapeutics Inc.
-- 29.6% Overall Response Rate Including 9.6% Complete Response Rate -- -- Amongst the Patients with Complete or Partial Response, Median Duration of Response was 9.2 Months and Median Overall...
Karyopharm Reports Third Quarter 2018 Financial Results and Highlights Recent Company Progress
November 08, 2018 07:00 ET
|
Karyopharm Therapeutics Inc.
-- U.S. Food and Drug Administration Accepts Karyopharm’s New Drug Application for Selinexor and Grants Priority Review; Assigns PDUFA Action Date of April 6, 2019 -- -- Fast Track Designation...
Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
November 07, 2018 08:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)...
Karyopharm to Present at the Jefferies 2018 London Healthcare Conference
November 07, 2018 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive...
Karyopharm Therapeutics to Ring Nasdaq Closing Bell on November 6th
November 05, 2018 07:00 ET
|
Karyopharm Therapeutics Inc.
Ceremony to Commemorate Five-Year Listing Anniversary NEWTON, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today...
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 02, 2018 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s...
Karyopharm Announces Results of Clinical Studies Investigating Selinexor in Multiple Myeloma and Diffuse Large B-Cell Lymphoma to be Presented at the American Society of Hematology 2018 Annual Meeting
November 01, 2018 10:17 ET
|
Karyopharm Therapeutics Inc.
-- Top-line Results from Phase 2b SADAL Study in DLBCL to be Presented -- -- Additional Results from the Pivotal Phase 2b STORM Study in Penta-Refractory Multiple Myeloma and Updated Phase 1b/2...
Karyopharm to Report Third Quarter 2018 Financial Results on November 8, 2018
November 01, 2018 07:00 ET
|
Karyopharm Therapeutics Inc.
-- Conference Call Scheduled for Thursday, November 8, 2018 at 8:30 a.m. ET -- NEWTON, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage...